Publications by authors named "Avner Reshef"

Claim this Profile
G
Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.
Danny M Cohn, Avner Reshef, Petra Staubach, William R Lumry, Henrike Feuersenger

J Allergy Clin Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final results.
Henriette Farkas, Jonny G Peter, Marcin Stobiecki, John Anderson, Emel Aygören-Pürsün, Avner Reshef

Ann Allergy Asthma Immunol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.
Mar Guilarte, William R Lumry, Markus Magerl, Inmaculada Martinez Saguer, Avner Reshef

Allergy Asthma Proc· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment.
Bruce L Zuraw, Konrad Bork, Laurence Bouillet, Sandra C Christiansen, Henriette Farkas, Avner Reshef

Clin Rev Allergy Immunol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
Avner Reshef, Connie Hsu, Constance H Katelaris, Philip H Li, Markus Magerl

Allergy· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus.
Avner Reshef, Thomas Buttgereit, Stephen D Betschel, Teresa Caballero, Henriette Farkas

J Allergy Clin Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
Marc A Riedl, Raffi Tachdjian, William R Lumry, Timothy Craig, Gül Karakaya, Avner Reshef

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema.
Remy S Petersen, Lauré M Fijen, Christian Apfelbacher, Markus Magerl, Karsten Weller, Avner Reshef

J Allergy Clin Immunol Pract· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Timothy J Craig, Donald S Levy, Avner Reshef, William R Lumry, Inmaculada Martinez-Saguer

Lancet Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Timothy J Craig, Avner Reshef, H Henry Li, Joshua S Jacobs, Jonathan A Bernstein

Lancet· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prodromes predict attacks of hereditary angioedema: Results of a prospective study.
Iris Leibovich-Nassi, Hava Golander, Avner Reshef

Allergy· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New medications to mitigate attacks of hereditary angioedema: does one size fit all?
Avner Reshef, Anete S Grumach

Lancet· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.
Marcus Maurer, Markus Magerl, Stephen Betschel, Werner Aberer, Ignacio J Ansotegui, Avner Reshef

Allergy· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prodromes as predictors of hereditary angioedema attacks.
Iris Leibovich-Nassi, Avner Reshef, Raz Somech, Hava Golander

Allergy· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Timothy Craig, Markus Magerl, Donald S Levy, Avner Reshef, William R Lumry

Lancet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.
Marcus Maurer, Markus Magerl, Stephen Betschel, Werner Aberer, Ignacio J Ansotegui, Avner Reshef

World Allergy Organ J· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Enigma of Prodromes in Hereditary Angioedema (HAE).
Iris Leibovich-Nassi, Avner Reshef

Clin Rev Allergy Immunol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA).
Iris Leibovich-Nassi, Hava Golander, Raz Somech, Dov Har-Even, Avner Reshef

Clin Rev Allergy Immunol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema.
Henriette Farkas, Avner Reshef, Teresa Caballero, María C Ortega López, Aharon Kessel

Pediatr Allergy Immunol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema.
Ankur Kumar Jindal, Avner Reshef, Hilary Longhurst,

Clin Rev Allergy Immunol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Mitigating Disparity in Healthcare Resources Between Countries for Management of Hereditary Angioedema.
Ankur Kumar Jindal, Avner Reshef, Hilary Longhurst, Gehm Workgroup Global Equity In H A E Management

Clin Rev Allergy Immunol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers in Hereditary Angioedema.
Grzegorz Porebski, Mateusz Kwitniewski, Avner Reshef

Clin Rev Allergy Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
Henriette Farkas, Marcin Stobiecki, Jonny Peter, Tamar Kinaciyan, Marcus Maurer, Avner Reshef

Clin Transl Allergy· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters.
Avner Reshef, Donald Levy, Hilary Longhurst, Marco Cicardi, Timothy Craig

Thromb Haemost· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
Donald Levy, Teresa Caballero, Iftikhar Hussain, Avner Reshef, John Anderson

Pediatr Allergy Immunol Pulmonol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis